Xenon Pharmaceuticals Inc.
XENE · XNASCIK 1582313fmd_12BPQ6MWXE2AHXSZTSDAPFVY4RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 0 | – | 7 | 32 | 18 | 9 | 0 | 0 | 8 |
| Research and development | 20 | 26 | 24 | 39 | 51 | 75 | 106 | 168 | 210 | 301 |
| Total operating expenses | 27 | 33 | 38 | 50 | 63 | 97 | 139 | 214 | 279 | 381 |
| Operating income | (25) | (33) | (38) | (43) | (31) | (79) | (129) | (214) | (279) | (373) |
| Interest expense | – | – | 1 | 1 | 0 | – | – | – | – | – |
| Interest and investment income | 1 | 0 | 1 | 2 | 2 | 0 | 9 | 28 | 42 | 27 |
| Other non-operating income (expense) | – | – | – | – | 2 | 0 | 4 | 31 | 41 | 28 |
| Income before taxes | – | – | (35) | (42) | (29) | (79) | (125) | (183) | (238) | (345) |
| Income tax expense | – | – | (0) | (0) | (0) | (0) | 0 | (0) | (4) | 1 |
| Net income from continuing operations | – | – | (34) | (42) | (29) | (79) | (125) | (182) | (234) | (346) |
| Net income | (23) | (31) | (34) | (42) | (29) | (79) | (125) | (182) | (234) | (346) |
| Net income to common shareholders | (23) | (31) | (32) | (40) | (28) | (77) | (125) | (182) | (234) | – |